AUROPHARMA

Aurobindo Pharma Limited

Source: NSE · Updated 4 Nov, 11:32 pm IST

Filed 4 Nov, 07:53 pm IST Q2 FY27 (Sep ’26)Consolidated₹ millions

Revenue

1,02,632.9

▲ 23.9% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

21,557.5

▲ 28.5% vs Q2 FY26

Net profit

11,238.4

▲ 32.5% vs Q2 FY26

EPS (₹)

19.57

▲ 33.9% vs Q2 FY26

Operating margin

21.0%

+70 bps vs Q2 FY26

Net margin

11.0%

+80 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+24% vs Q2 FY26 · +12% vs Q1 FY27

Profit+33% vs Q2 FY26 · +9% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals and the filing PDF.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	1,02,632.9	91,503.5	▲ 12.2%	82,857	▲ 23.9%
Other income	1,682.2	2,642.3	▼ 36.3%	1,205.9	▲ 39.5%
Total expenses	87,409	78,577.7	▲ 11.2%	71,320.3	▲ 22.6%
Operating profit (EBITDA)*	21,557.5	18,810.6	▲ 14.6%	16,781	▲ 28.5%
Tax expense	5,638.3	4,830.6	▲ 16.7%	4,277.9	▲ 31.8%
Net profit	11,238.4	10,320.3	▲ 8.9%	8,481.3	▲ 32.5%
EPS (₹)	19.57	17.86	▲ 9.6%	14.61	▲ 33.9%
Operating margin	21.0%	20.6%	+40 bps	20.3%	+70 bps
Net margin	11.0%	11.3%	−30 bps	10.2%	+80 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ millions except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Aurobindo Pharma results, dividends & filings ›

Other results filed 4 Nov

CUMMINSIND Cummins India Limited›AUSOMENT Ausom Enterprise Limited›TENNIND Tenneco Clean Air India Limited›UNIVCABLES Universal Cables Limited›TREL Transindia Real Estate Limited›ESABINDIA Esab India Limited›MAXESTATES Max Estates Limited›AUGMONT Augmont Enterprises Limited›TCC TCC Concept Limited›WANBURY Wanbury Limited›LCL Lohia Corp Limited›SHUKRAPHAR Shukra Pharmaceuticals Limited›

Today's results ›

AUROBINDO PHARMA Q2 FY27 ; NET PROFIT UP 33% AT ₹1,124 CR (YOY), UP 9% (QOQ)

REVENUE UP 24% AT ₹10,263 CR (YOY), UP 12% (QOQ)

EBITDA UP 28% AT ₹2,156 CR (YOY), UP 15% (QOQ)

MARGINS AT 21.0% VS 20.3% (YOY), 20.6% (QOQ)

https://resultkal.com/r/auropharma-2026-11-04
Source: NSE filing · not investment advice

FAQ

When did Aurobindo Pharma announce Q2 FY27 results?

Aurobindo Pharma filed its results on NSE on 4 Nov, 07:53 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Aurobindo Pharma figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← AUROPHARMA overview